New publication by Gradientech and Uppsala University on rapid AST platform
Uppsala, February 26, 2020. Gradientech today announces the scientific publication of a navel multiplex fluidic chip for rapid antibiotic susceptibility testing (ASn. The chip can generate AST results within 2-4 ho urs, which is at least 20 hours faster than current AST methods used in hospital laboratories.
There is an unmet need for faster and more precise AST methods that can determine which antibiotics will be mast effective against a bacterial infection in a timely man ner. This is particularly important for time-critical conditions like sepsis, where every minute without appropriate treatment reduces the chance of survival.
The results obtained with the multiplex fluidic chip serve as a proof-of-concept for the commercial QuickMIC® AST system that Gradientech is currently developing, which is based on the same proprietary technology. This rapid AST technology has the potential to enable faster and targeted treatment initiation in sepsis patients, thereby contributing to improved clinical outcomes, reduced healthcare costs and help in the fight against antibiotic resistance.
The study findings have been published in mBio, a prestigious open access journal from the American Society for Microbiology. To access the full article, follow the link below:
https://mbio.asm.org/content/11/1/e03109-19
For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se
